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Shc homology 2-containing inositol 5´ phosphatase-2 (SHIP2) is as lipid phosphatase which 
inhibits insulin signaling downstream of phosphoinositide-3-kinase (PI3K); its role in 
vascular function is poorly understood. To examine its role in endothelial cell (EC) biology, 
we generated mice with catalytic inactivation of one SHIP2 allele selectively in EC 
(ECSHIP2Δ/+). Hyperinsulinemic euglycemic clamping studies revealed ECSHIP2Δ/+ were 
resistant to insulin-stimulated glucose uptake in adipose tissue and skeletal muscle, compared 
with littermate controls. EC from ECSHIP2Δ/+ had increased basal expression and activation 
of PI3K downstream targets, including Akt and endothelial nitric oxide synthase (eNOS), 
although incremental activation by insulin and shear stress was impaired. Insulin-mediated 
vasodilation was blunted in ECSHIP2Δ/+, as was aortic nitric oxide bioavailability. 
Acetylcholine-induced vasodilation was also impaired in ECSHIP2Δ/+, which was exaggerated 
in the presence of a superoxide dismutase/catalase mimetic. Superoxide abundance was 
elevated in ECSHIP2Δ/+ EC, and was suppressed by PI3K and Nox2 NADPH oxidase 
inhibitors. These findings were phenocopied in healthy human EC after SHIP2 silencing. Our 
data suggest that endothelial SHIP2 is required to maintain normal systemic glucose 





Insulin resistance is a pathophysiological hallmark of obesity and type 2 diabetes mellitus (1). 
When systemic (2,3), or endothelium-restricted (4,5), insulin resistance leads to an 
unfavorable imbalance between endothelial cell (EC) generation of the signaling radical nitric 
oxide (NO) and potentially cytotoxic oxidants such as superoxide (4,5), and hydrogen 
peroxide (6). Whilst the effects of whole body and cell-specific insulin resistance on EC 
function are appreciated, the local and systemic consequences of increased insulin signaling in 
EC are less well characterized. To address this, we generated mice with endothelium-
restricted inhibition of Shc homology 2-containing inositol 5´phosphatase 2 (SHIP2). SHIP2 
is a lipid phosphatase which catalyzes the removal of the 5’ phosphate group from 
phosphatidylinositol(3,4,5)-trisphosphate (PI(3,4,5)P3) (7). PI(3,4,5)P3 accumulation promotes 
the activity of signaling molecules, such as Akt; by reducing PI(3,4,5)P3 accumulation, SHIP2 
acts as a negative regulator of insulin-induced Akt signaling (7). Indeed, transgenic mice 
over-expressing SHIP2 have reduced insulin tolerance and blunted Akt activation in classic 
insulin target tissues (8).  
 
Three different murine models of SHIP2 loss of function have been generated to examine the 
role of SHIP2 in insulin signaling. Clement et al described mice with deletion of Inppl1 
(which encodes SHIP2), although these had unplanned deletion of Phox2a, a transcription 
factor involved in normal development (9). Sleeman et al studied a second knockout mouse 
with deletion of Inppl1, but intact Phox2a; this also had developmental abnormalities (10). 
Recently, mice with catalytic inactivation of SHIP2 were generated by inserting Cre-
recombinase-specific loxP sites into introns flanking Inppl1 exons 18-19 (coding the SHIP2 
catalytic domain) (11); these also had substantial developmental abnormalities making 
conclusions regarding insulin signaling challenging.  
 
 
To improve our understanding of enhanced endothelial insulin signaling, whilst 
circumventing the developmental impact of global SHIP2 deletion, we generated mice in 
which the catalytically inactive SHIP2 described above (11) is restricted to EC using Tie2-Cre 
(referred to as ECSHIP2Δ/+). We hypothesized that endothelial SHIP2 activity is required to 
maintain appropriate systemic and vascular responses to insulin. 
 
Research Design and Methods 
Generating ECSHIP2Δ/+ mice. Mice were bred onto a C57BL/6J background for >10 
generations in a conventional animal facility with 12-hour light/dark cycle. To examine the 
effect of chronically increased insulin signaling, male mice aged 10 months were used in all 
experiments, unless stated otherwise, conducted in accordance with accepted standards of 
humane animal care under UK Home Office project license 40/3523. A catalytically inactive 
SHIP2 mutant mouse was generated by inserting Cre recombinase-specific loxP sites into 
intronic regions flanking exons 18-19 of the Inppl1 gene (11);  mice with one floxed allele  
(SHIP2(18-19)/+) were crossed with Tie2-Cre mice (Jackson Labs) to produce progeny with 
germline endothelium-specific SHIP2 inactivation (referred to as ECSHIP2Δ/+). Cre-positive 
SHIP2+/+ littermates were controls in all experiments.  
 
Metabolic tests. Glucose and insulin tolerance tests were performed by blood sampling after 
intraperitoneal (IP) injection of glucose (1mg/g) or recombinant human insulin (0.75unit/kg: 
Actrapid; Novo Nordisk) respectively, as described (4,5). Glucose concentrations were 
determined in whole blood by a portable meter (Roche). Plasma insulin concentrations were 
determined by enzyme-linked immunoassay (CrystalChem). Free fatty acids and triglycerides 
were measured in fasting plasma using colorimetric assays (Abcam) (12). 
 
 
In vivo hyperinsulinaemic euglycaemic clamp studies. In vivo euglycaemic insulin clamps 
were performed at the Mouse Metabolic Phenotyping Centre at Vanderbilt University, as 
described (13). These use tracer techniques to assess: 1) Whole body insulin sensitivity; 2) 
Insulin suppression of endogenous (i.e. hepatic) glucose production; 3) Rates of individual 
tissue glucose uptake.  
 
Experimental protocol: Mice were maintained on a chow diet (Harlan Teklad Diet 7012). 
Catheters were implanted in a carotid artery for blood sampling, and jugular vein for 
infusions, 5 days before the study. On the morning of each study, food was removed and 
clamps initiated after a 5-h fast. 120 minutes (t=-120 min) prior to initiation of clamps, 
animals received a bolus (1.5μCi), followed by a continuous (0.075μCi/min) infusion of [3-
3H] glucose. Baseline blood or plasma parameters were determined in blood samples collected 
at −10 and 0min. At t=0 an insulin infusion (4mU/kg/min) was started, the [3-3H]glucose 
infusion rate increased (0.15μCi/min), and a constant infusion of heparinized saline-washed 
with erythrocytes from donor animals (5.5μL/min) given to prevent a fall in hematocrit. These 
infusions were continued for the duration of the clamp (145min). Blood glucose was clamped 
at ~100-110mg/dL using variable glucose infusion rate (GIR). Blood glucose was monitored 
every 10 minutes to validate clamping, and GIR adjusted accordingly. Blood was taken 
between 80–120min for determination of [3-3H]glucose. Clamp insulin was determined at 
t=120 and 145min. At 120min 13μCi 2[14C]deoxyglucose ([14C]2DG) was administered as an 
intravenous bolus. Blood was taken between 122–145min for determination of [14C]2DG. 
After the last sample, mice were euthanized and tissues collected.  
 
Plasma and muscle sample analysis: Immunoreactive insulin was assayed with rat 
radioimmunoassay kit (Millipore). To measure plasma 3-[3H]-D-glucose, the sample was 
deproteinized with barium hydroxide (Ba(OH)2) and zinc sulfate (ZnSO4), dried, and 
 
radioactivity determined using liquid scintillation counting. Excised soleus, gastrocnemius, 
superficial vastus lateralis and gonadal adipose tissue, were deproteinized with percholoric 
acid and then neutralizated to pH~7.5. A portion of the extract was counted ([2-14C]DG and 
[2-14C]DG-G-phosphate ([2-14C]DGP) and a portion treated with Ba(OH)2 and ZnSO4 and the 
supernatant counted ([2-14C]DG). Both [2-14C]DG and [2-14C]DG-G-phosphate ([2-14C]DGP) 
radioactivity levels were determined using liquid scintillation counting. 
 
Studies of vasomotor function in aortic rings. Vasomotor function was assessed ex vivo in 
aortic rings as described (2–5). Rings were mounted in an organ bath containing Krebs-
Henseleit buffer (composition [in mmol/L]: NaCl 119, KCl 4.7, KH2PO4 1.18, NaHCO3 25, 
MgSO4 1.19, CaCl2 2.5, and glucose 11.0) and gassed with 95% O2/5% CO2. Rings were 
equilibrated at a resting tension of 3g for 45min. A cumulative dose response to the 
constrictor phenylephrine (PE) (1nmol/L to 10mol/L) was performed. Vasodilation to 
insulin was assessed with incremental doses of actrapid insulin (0.1-1000mU/ml) in aortic 
segments pre-constricted maximally with PE. Relaxation responses to cumulative addition of 
acetylcholine (1nmol/L-10µmol/l) and sodium nitroprusside (0.1nmol/L-1µmol/l) were 
performed. The effects of MnTmPyP (10μmol/L for 30min, Calbiochem) on aortic relaxation 
were examined, as previously reported (2). Relaxation responses are expressed as % 
decrement in pre-constricted tension. Bioavailable NO in aortic segments subject to isometric 
tension was measured by recording the increase in tension elicited by L-NMMA (0.1mM) in 
aortic segments maximally pre-constricted with PE. 
 
Amplex red assay for hydrogen peroxide in aorta. H2O2 was measured using an Amplex® 
Red Hydrogen Peroxide/Peroxidase Assay Kit (ThermoFisher), according to the 
manufacturer’s protocol. Freshly harvested aortae were collected into modified Krebs-HEPES 
buffer, containing 20mM HEPES, 119mM NaCl, 4.6mM KCl, 1mM MgSO4.7H2O, 0.15mM 
 
Na2HPO4, 0.4mM KH2PO4, 5mM NaHCO3, 1.2mM CaCl2 and 5.5mM glucose, pH 7.4. 
Aortas were cleaned of adipose tissue and divided into 2mm rings. Rings were incubated in 
50µL of modified Krebs-HEPES buffer with half also receiving 1250U/mL catalase (free 
from tymol) for 1h at 37°C. 50µL freshly-prepared 100μM Amplex Red reagent with 
0.2U/mL HRP was added to samples and incubated for 1 hour at 37°C, protected from light. 
Rings were removed from the samples and fluorescence measured on a VarioSkan 
(ThermoFisher) plate reader (excitation/emission 530/590nm). The mean reading with 
catalase was subtracted from the mean without catalase, and this value plotted on a 
simultaneously prepared H2O2 standard curve. Dry tissue mass was used for normalization 
(12). 
 
Pulmonary endothelial cell isolation and culture. Primary endothelial cells were isolated 
from lungs by immunoselection with CD146-antibody-coated magnetic beads as reported 
(4,14) and cultured in 2ml EGM-2-MV (Lonza) supplemented with 5% fetal calf serum until 
confluent. These express a range of endothelial markers including eNOS, Tie2 and CD102 
protein (4,14). 
 
SHIP2 activity assay. SHIP2 activity was measured using the 5’PtdIns(3,4,5)P3 Phosphatase 
Activity Fluorescent Polarization Assay (Echelon Biosciences) according to the 
manufacturer’s instructions, using a Polarstar Optima plate reader (BMG Labtech) with 
excitation at 550nm and measuring polarized emission at 580nm. 
 
Nitric oxide synthase activity in endothelial cells. Active eNOS produces NO and L-
citrulline from L-arginine in a stoichiometric reaction. Insulin-stimulated eNOS activity in EC 
was determined by conversion of [14C]-L-arginine to [14C]-L-citrulline as described (14,15). 
EC (1x106) were incubated at 37°C for 20 min in HEPES buffer pH 7.4 (in mmol/L): 10 
 
HEPES, 145 NaCl, 5 KCl, 1 MgSO4, 10 glucose, 1.5 CaCl2 containing 0.25% BSA. 0.5 
μCi/ml [14C]-L-arginine was then added for 5min prior to stimulation with insulin 
(100nmol/L) for 15min before the reaction was stopped with cold phosphate-buffered saline 
(PBS) containing 5mmol/L unlabeled L-arginine and 4mmol/L EDTA, after which cells were 
denatured in 95% ethanol. After evaporation, the pellet was dissolved in 20mmol/L HEPES-
Na+ (pH 5.5) and applied to a well-equilibrated DOWEX (Na+ form) column. The eluate 
[14C]-L-citrulline content was quantified by liquid scintillation and normalized against total 
protein mass.  
 
Exposure of endothelial cells to flow-mediated shear stress. Pulmonary EC were seeded 
onto fibronectin-coated 6-well plates. Confluent monolayers were placed onto an orbital 
rotating platform (Grant Instruments) inside an incubator (16). The radius of orbit of the 
orbital shaker was 10mm and the rotation rate set to 210rpm for 10min, generating a shear 
force of 12 dyne/cm2.  
 
Lucigenin enhanced chemiluminescence. We used lucigenin (5μM), enhanced 
chemiluminescence to measure NAD(P)H-dependent superoxide production in pulmonary 
EC, as described (12). All experiments were performed in triplicate. Pulmonary EC were 
suspended in PBS containing 5% FCS, 0.5% BSA and 50uM gp91ds-tat (GenScript) or 
scrambled ds-tat peptide (GenScript) and incubated in 37˚C for 30min. Luminescence was 
measured upon addition of a non-redox cycling concentration of lucigenin (5µM) and 
NADPH (100µM), using an autodispenser (VarioSkan, ThermoFisher).  
 
Cell lysis, immunoblotting, and immunoprecipitation. Pulmonary EC were lysed in 
extraction buffer containing (in mmol/L, unless otherwise specified) 50 HEPES, 120 NaCl, 1 
MgCl2, 1 CaCl2, 10 NaP2O7, 20 NaF, 1 EDTA, 10% glycerol, 1% NP40, 2 sodium 
 
orthovanadate, 0.5 μg/mL leupeptin, 0.2 phenylmethylsulfonyl fluoride, and 0.5 μg/mL 
aprotinin. Cell extracts were sonicated in an ice bath and centrifuged for 15 min, before 
protein measurement using the biocinochinic acid assay (ThermoFisher). Equal amounts of 
protein were resolved on SDS-polyacrylamide gels (ThermoFisher) and transferred to 
polyvinylidine difluoride membranes. Immunoblotting was carried out with primary 
antibodies produced by Cell Signaling Technologies, except for: mouse NOX2, mouse insulin 
receptor, mouse IRS1, mouse IRS2 and human SHIP2 (Abcam); human NOX2 and β-actin 
(Santa Cruz Biotechnology); mouse SHIP2 (Gift from Stéphane Schurmans, Université de 
Liège, Belgium). Blots were incubated with appropriate peroxidase-conjugated secondary 
antibodies and developed with enhanced chemiluminescence (Millipore). 
 
Lentiviral knockdown of SHIP2 in human umbilical vein endothelial cells. Knockdown of 
SHIP2 in human umbilical vein endothelial cells (HUVEC; Promocell, UK) was performed 
with shRNA transduction using a lentivirus vector (Sigma-Aldrich SHCLNV-NM001567), as 
described (17). HUVEC were transduced with 10 MOI and incubated at 37ºC for 4 days prior 
to analysis. Control cells were transduced with GFP-targeting control shRNA lentivirus 
(Sigma-Aldrich SHC002H). 
 
Gene expression. mRNA was isolated using TRIzol (ThermoFisher), and SHIP2 mRNA 
quantified using SYBR-Green based real-time quantitative PCR using (ABI Prism 7900HT, 
Applied Biosystems) (4). Primer details are as follows: truncated SHIP2 forward 5’-ACC-
TTA-ACT-ACC-GCT-TAG-ACA-TGG-A; truncated SHIP2 reverse 5’-ATC-AGT-GCA-
ACT-AAA-TCG-AAG-GAA; non-truncated region of SHIP2 forward 5’-AAG-ACT-ACT-
CGG-CGG-AAC-CA; non-truncated region of SHIP2 reverse 5’- TGC-CGA-TCA-CCC-
AAC-GA; β-actin forward 5’-CGT-GAA-AAG-ATG-ACC-CAG-ATC-A; β-actin reverse 5’-
TGG-TAC-GAC-CAG-AGG-CAT-ACA-G. As published (12), RNA was also isolated from 
 
purified CD11b+ myeloid cells to define truncated SHIP2 expression. TaqMan 
(ThermoFisher) assays were used to measure expression of IL-1β (mm00434228_m1), IL-6 
(mm00446190_m1) and TNFα (mm00443258_m1) in gastrocnemius muscle and epididymal 
adipose tissue.  
 
Flow cytometry. Heparinised whole blood underwent erythrocyte lysis (Pharmalyse, BD 
Biosciences) prior to isolation of peripheral blood mononuclear cells (PBMC) by 
centrifugation. After blocking with CD16/32 Fc block (BD Biosciences), cells were stained 
anti-CD45-VioBlue, anti-CD11b-FITC, anti-Ly6G-PE (all Miltenyi Biotec) and Ly6C-APC 
(eBioscience). Paired samples were prepared with corresponding isotype-specific controls. 
Flow cytometry (LSRFortessa, BD Biosciences) was performed to define the following 
subsets: total leukocytes (CD45+); myeloid cells (CD45+CD11b+); monocytes 
(CD45+CD11b+Ly6G-Ly6C+); neutrophils (CD45+CD11b+Ly6Ghi-Ly6Chi); ‘inflammatory’ 
monocytes (CD45+CD11b+Ly6G-Ly6Chi); ‘patrolling’ monocytes (CD45+CD11b+Ly6G-
Ly6Clo). All populations are expressed as cells/ml blood. 
 
Cytokine ELISA. Serum IL-6 and TNFα were measured with commercially available 
ELISAs according to manufacturers’ instructions (Abcam) (12). 
 
Histology. 1) Adipose inflammation. Epididymal fat fixed in 4% paraformaldehyde was 
embedded in paraffin blocks and 5-micron sections stained with Sirius Red (Sigma) to 
demarcate collagen deposition, a feature of inflammation (18). Sirius red percentage area 
staining was calculated with Image J (NIH). 2) Adipose vascularity. Epididymal fat fixed in 
1% paraformaldehyde, then stained with lipidtox-green (ThermoFisher) and isolectin-B4-
Alexa647 (ThermoFisher) was wholemounted in chamber slides and imaged with confocal 
microscopy (Zeiss LSM880). Vascular (Isolectin-B4) percentage area was calculated in 
 
thresholded 4-micron maximum intensity projections using ImageJ (NIH). 3) Skeletal muscle 
vascularity. Gastrocnemius muscle fixed in 4% paraformaldehyde was embedded in OCT 
(TissueTek, Sakura) and snap-frozen. 5-micron cryosections were stained with isolectin-B4-
Alexa647 (ThermoFisher) and DAPI (Southern Biotech) then imaged with confocal 
microscopy (Zeiss LSM880). Vascular (Isolectin-B4) percentage area was calculated in 
thresholded 2-micron maximum intensity projections using ImageJ (NIH). 
 
Statistics. Results are expressed as mean (SEM). Comparisons within groups were made 
using paired Student’s t-tests and between groups using unpaired Student’s t-tests or repeated-
measures ANOVA, as appropriate. P<0.05 was considered statistically significant. 
 
Results 
Basic characterization of mice with endothelium-specific inactivation of SHIP2. To 
examine the effect of reducing the restraining role of SHIP2 on insulin action specifically in 
the endothelium, we generated mice with Tie2-Cre mediated catalytic inactivation of one 
SHIP2 allele (ECSHIP2Δ/+). ECSHIP2Δ/+ mice were born with the same frequency as control 
littermates. There was no difference in gross appearance (Fig. 1A), organ weight (Fig. 1B), or 
body length (Fig. 1C), when comparing ECSHIP2Δ/+ and control, although 10 month-old 
ECSHIP2Δ/+ mice were slightly heavier (Fig. 1D). We quantified truncated SHIP2 mRNA in 
organs with differing vascularity; as expected, SHIP2Δ18-19 mRNA was only detectable above 
non-specific fluorescence in ECSHIP2Δ/+ organs, not control organs (Fig. 1E). SHIP2Δ18-19 
mRNA was also undetectable in non-endothelial cells from ECSHIP2Δ/+ lungs (Fig. 1F), but 
was just detectable in CD11b+ myeloid cells (>3000-fold lower than ECSHIP2Δ/+ PEC, and 
≈5-fold above non-specific fluorescence Sup. Fig. 1A). Endothelial SHIP2 protein expression 
was mildly reduced in ECSHIP2Δ/+ mice (Fig. 1G), whilst SHIP2 activity was substantially 
 
reduced (Fig. 1H), in keeping with targeted catalytic domain deletion, as shown previously in 
work using SHIP2(18-19)/+ mice (11). 
 
ECSHIP2Δ/+ mice do not exhibit a pro-inflammatory state. As very low-level expression of 
truncated SHIP2 was found in myeloid cells, we conducted a detailed assessment of systemic 
and tissue-specific inflammation. Flow cytometry revealed no difference in circulating 
leukocyte populations (Sup. Fig. 1B), and leukocyte SHIP2 activity was comparable in 
ECSHIP2Δ/+ and control littermates (Sup. Fig. 1C). ECSHIP2Δ/+ had normal serum TNFα and 
IL-6 (Sup. Fig. 1D-E), along with expression of TNFα, IL-1β, and IL-6 in white adipose 
tissue and skeletal muscle (Sup. Fig. 1F). We found no evidence of altered adipose tissue 
inflammation using Sirius Red collagen staining (Sup. Fig. 1G). 
 
ECSHIP2Δ/+ mice have reduced glucose tolerance and insulin sensitivity. Compared to 
control littermates, ECSHIP2Δ/+ mice had higher fasting glucose (Fig. 2A), similar fasting 
insulin concentrations (Fig. 2B), and higher HOMA-IR (Fig. 2C). ECSHIP2Δ/+ had delayed 
normalization in capillary glucose during glucose tolerance testing (Fig. 2D), but insulin 
tolerance rests were similar to control littermates (Fig. 2E). Serum free fatty acids (Fig. 2F) 
and triglycerides (Fig. 2G) were not altered in ECSHIP2Δ/+. In hyperinsulinemic euglycemic 
clamp studies, ECSHIP2Δ/+ mice required approximately 25% less glucose to maintain 
euglycemia than controls (Fig. 3A). In tracer studies, glucose uptake into adipose tissue and 
skeletal muscle was reduced (Fig. 3B), whereas hepatic glucose output was no different 
between ECSHIP2Δ/+ and controls (Figs. 3C,D).  
 
Endothelial cells from ECSHIP2Δ/+ mice have increased basal activation of signaling 
molecules downstream of PI3K, although incremental activation by insulin and shear 
stress is impaired. In the endothelium, PI3K transduces insulin signaling by catalyzing the 
 
addition of a phosphate group to the 3’-position of inositol rings, generating 3’-
phosphoinositides, including PI(3,4,5)P3, which by activating phosphoinositide dependent 
kinase-1 (PDK1) activates the serine/threonine kinase Akt/PKB (19). Akt activates 
downstream signaling molecules including eNOS (20). ECSHIP2Δ/+ had increased basal 
expression of total PDK1 and pPDK1, total Akt and T308 pAkt, total eNOS and S1177 
peNOS, Rictor (which phosphorylates Akt at S473) and pRictor (Fig. 4A). Importantly, 6-
week old ECSHIP2Δ/+ mice had normal endothelial total Akt, Rictor and eNOS expression, 
and normal adipose tissue and skeletal muscle vascularity (Sup. Fig. 2), suggesting adulthood 
signaling abnormalities do not reflect persistent developmental abnormalities. ECSHIP2Δ/+ 
had comparable insulin-stimulated induction of Akt S473 phosphorylation, but diminished 
downstream induction of eNOS S1177 phosphorylation, compared to control (Fig. 4B). 
PI3K/Akt also mediate shear-induced eNOS activation in EC; ECSHIP2Δ/+ EC exhibited no 
increase in the phosphorylation of Akt S473 or eNOS S1177 in response to shear stress (Fig. 
4C). Notably, we found no significant differences in basal or insulin-stimulated 
phosphorylation of the insulin receptor or insulin receptor substrates 1/2 (Sup. Fig. 3). 
 
ECSHIP2Δ/+ mice have blunted acetylcholine- and insulin-mediated aortic vasodilatation 
associated with vascular oxidative stress. Ex vivo aortic vasomotor responses were studied 
in organ bath apparatus. Consistent with our findings in EC, ECSHIP2Δ/+ had blunted insulin-
mediated vasodilation (Fig. 5A). ECSHIP2Δ/+ exhibited significantly less constriction to the 
non-selective NOS inhibitor L-NMMA (Figs. 5B-D), indicative of reduced NO biogenesis in 
response to isometric tension. There was subtle impairment of acetylcholine-induced 
relaxation in ECSHIP2Δ/+ (Fig. 5E), but SNP responses were comparable to control (Fig. 5F). 
To explore whether vasodilating oxidants were masking more substantial impairment of 
acetylcholine-mediated vasodilation in ECSHIP2Δ/+, we repeated acetylcholine relaxation 
studies in the presence of the superoxide dismutase/catalase mimetic MnTmPyP. MnTmPyP 
 
reduced acetylcholine-mediated aortic relaxation in ECSHIP2Δ/+ and control vessels, but the 
extent of inhibition was significantly greater in ECSHIP2Δ/+ (Figs. 5G-K). Hydrogen 
peroxide, the more stable product of superoxide dismutation, was also elevated in 
ECSHIP2Δ/+ aortae (Fig. 5L). In isolated lung EC, superoxide abundance was increased, as 
assessed by lucigenin-enganced chemiluminescence and with dihydroethedium fluorescence 
(Fig. 6A). Superoxide is generated by many enzymes, and we have shown Nox2 NADPH 
oxidase is a critical pathophysiological source of superoxide in models of global insulin 
resistance (4,5). In ECSHIP2Δ/+ EC, Nox2 protein expression was increased (Fig. 6B). 
Moreover, superoxide abundance was normalized with the Nox2 specific inhibitor Gp91ds-tat 
(Fig. 6C), and the PI3K inhibitors Wortmannin and LY294002 (Fig. 6D). Oxidative stress is 
often associated with reduced eNOS activity, and this was confirmed in ECSHIP2Δ/+ EC 
treated with insulin (Fig. 6E).  
 
SHIP2 knockdown in human EC phenocopies the signaling abnormalities of 
ECSHIP2Δ/+. Next, we sought to validate and generalize the mechanistic data from our 
murine model, using a complementary system in human endothelial cells. We used lentiviral 
vectors to express SHIP2-targeting shRNA, or a non-targeting control shRNA, to knockdown 
SHIP2 in HUVEC, achieving ≈75% reduction in SHIP2 protein, versus control (Fig. 7A). As 
seen in ECSHIP2Δ/+ EC, knockdown of SHIP2 reduced SHIP2 activity (Fig. 7B), and 
enhanced superoxide concentrations (Fig. 7C). We examined potential sources of superoxide, 
and again demonstrated increased Nox2 NADPH oxidase expression (Fig. 7D); moreover, the 
excess superoxide seen in SHIP2 deficient cells was inhibited by Gp91ds-tat (Figs. 7E,F). 
Furthermore, in SHIP2 knockdown HUVEC, S473 pAkt and S1177 peNOS were more 
abundant (Fig. 7G), and superoxide abundance was reduced by the PI3K inhibitors 
Wortmannin and LY294002 (Fig. 7H). These data imply increased PI3K signaling drives 




We provide a number of novel findings pertaining to the understanding of endothelial SHIP2 
signaling and metabolic disease: 1) EC-specific reduction of SHIP2 activity is not associated 
with developmental defects; 2) Mice with EC-specific reduction of SHIP2 activity develop 
insulin resistance in skeletal muscle and fat, which is not associated with evidence of 
inflammation; 3) EC-specific reduction of SHIP2 activity is associated with endothelial 
dysfunction, excess superoxide abundance, and reduced NO bioavailability; 4) Oxidative 
stress associated with SHIP2 knockdown in murine and human EC is caused by excessive 
PI3K signaling, and is Nox2 NADPH oxidase-dependent. Our data emphasize the detrimental 
impact of increased PI3K/Akt signaling on EC function, and confirm the key role of SHIP2 in 
maintaining vascular homeostasis. In particular, they reveal that increased basal PI3K/Akt 
signal transduction in EC is associated with Nox2-mediated vascular oxidative stress and 
paradoxical systemic insulin resistance due to impaired adipose tissue and skeletal muscle 
glucose uptake. Therefore, whilst hyperinsulinemia is an adaptive response to hyperglycemia, 
when sustained this may have detrimental effects on vascular function and glucose uptake in 
key metabolic tissues; this raises important questions about the long-term risks of therapies 
that induce sustained insulin signaling.  
 
SHIP2, insulin signaling, PI3-kinase and Akt. The ligand-bound insulin receptor 
phosphorylates tyrosine residues on downstream substrates, activating PI3K, which catalyzes 
phosphorylation of the 3’-position of inositol rings, generating 3’ phosphoinositides including 
PI(3,4,5)P3 (21). PI(3,4,5)P3 recruits the serine/threonine kinase Akt to the cell membrane, 
facilitating its activation, allowing phosphorylation of downstream effectors, including eNOS 
(19). Short-term in vivo studies have examined the effect of SHIP2 modulation on insulin 
sensitivity in models of type 2 diabetes. Adenoviral expression of a dominant-negative mutant 
 
SHIP2 in the liver of obese hyperglycemic mice restored insulin sensitivity and Akt 
phosphorylation (22), whereas expression of wild-type SHIP2 blunted these (23). In humans, 
SHIP2 (Inppl1) polymorphisms are associated with obesity, type 2 diabetes and the metabolic 
syndrome (24,25). SHIP2 inhibition has thus been suggested as an approach to treat insulin 
resistant type 2 diabetes mellitus (7). However, the effect of SHIP2 inhibition on specific 
components of the arterial wall is ill defined; our data question the potential therapeutic 
benefit of SHIP2 inhibition, at least in the endothelium.  
 
Endothelial SHIP2 inhibition and glucose homeostasis. We demonstrated that 10-month 
old ECSHIP2Δ/+ mice were resistant to insulin-mediated glucose lowering, and the vascular 
dysfunction caused by chronic SHIP2 inactivation may underpin these findings. We found 
reduced insulin-stimulated eNOS activation in ECSHIP2Δ/+ EC, and endothelial-derived NO 
is thought to be crucial for insulin-stimulated glucose uptake; eNOS deficient mice are 
systemically insulin resistant, with reduced insulin-mediated glucose uptake in skeletal 
muscle (26,27). Kubota et al demonstrated impaired insulin-stimulated glucose disposal in the 
skeletal muscle of mice with endothelium-specific deletion of insulin receptor substrate 2 
(IRS2), due to impaired NO bioavailability (28). Our dataset are consistent with this, since 
ECSHIP2Δ/+ mice have reduced EC insulin sensitivity, diminished insulin-stimulated glucose 
uptake to skeletal muscle, and reduced endothelial NO generation. However, mice with 
endothelium-specific insulin receptor deletion have normal glucose disposal during clamping 
studies (29), suggesting a complex association between vascular insulin signaling and 
systemic glucose homeostasis. Importantly, ECSHIP2Δ/+ mice had preserved proximal insulin 
signaling, implying that downstream signaling may be more important in vascular 
homeostasis, including regulation of systemic glucose metabolism. 
 
 
Endothelial SHIP2 inhibition, superoxide generation, and eNOS inhibition. We 
demonstrate that EC-specific inactivation of SHIP2 increases basal activation of the 
PI3K/Akt/eNOS signaling cascade, with potentially important increases in both the total and 
phosphorylated forms of key signaling nodes (which did not increase in response to insulin), 
and increases the abundance of superoxide. This is associated with reduced NO production in 
isolated EC, and aortic segments under isometric tension, indicating endothelial dysfunction. 
Expression of Nox2 NADPH oxidase was increased in the setting of SHIP2 knockdown, and 
by using the selective antagonist Gp91ds-tat, we implicated Nox2 as the source of excess 
superoxide. Moreover, by normalizing superoxide abundance using two selective PI3K 
inhibitors, we also implicated excessive PI3K/Akt signaling as contributing to oxidative 
stress. Whilst a number of studies have shown a link between excessive Akt activation and 
superoxide generation (30,31), none have identified the source of excess superoxide. 
Moreover, the association between SHIP2 and oxidative stress in vivo is currently unexplored. 
Our study is therefore the first to mechanistically link SHIP2 inactivation to increased Nox2 
NADPH oxidase activity, oxidative stress, and endothelial dysfunction (Fig. 8). By 
recapitulating these data in human EC after silencing SHIP2, we provide support for the 
relevance of our in vivo observations to human pathophysiology, suggesting caution is 
warranted in the clinical translation of SHIP2 inhibition. Importantly, we have also published 
that mice with endothelial overexpression of the insulin receptor exhibit many of the 
phenotypic traits noted in ECSHIP2Δ/+ mice, including PI3K- and Nox2-dependent vascular 
oxidative stress and endothelial dysfunction (12). In conjunction, these data suggest that 
unrestrained signaling at multiple nodes in the proximal insulin signaling cascade cause 
vascular dysfunction mediated by Nox2-dependent oxidative stress. 
 
 
Conclusion. Vascular endothelial SHIP2 activity is required to maintain normal systemic 
insulin sensitivity and suppress vascular oxidative stress and endothelial dysfunction caused 
by unrestrained PI3K-Nox2 signaling. 
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Figure 1: Basic characterization of mice with endothelial cell specific inactivation of Shc 
homology 2-containing inositol 5´ phosphatase 2 (ECSHIP2Δ/+). Compared to control Cre+ 
littermate controls: A) No difference was seen in gross development of ECSHIP2Δ/+; B) 
ECSHIP2Δ/+ organ weights were comparable (n≥7); C) Nose to tail length of ECSHIP2Δ/+ was 
similar (n≥4); D) ECSHIP2Δ/+ were slightly heavier (n≥6); E) Truncated SHIP2 mRNA was 
detectable in organs from ECSHIP2Δ/+, but not controls (n=3); F) Truncated SHIP2 mRNA 
was only detectable in EC from ECSHIP2Δ/+ lungs, and not the non-EC fraction (n=3); G) 
SHIP2 protein expression (Representative Western blot shown above panel) was mildly 
reduced in EC from ECSHIP2Δ/+ (n≥5); I) SHIP2 activity was substantially reduced in EC 
from ECSHIP2Δ/+ (n≥9). 
 
Figure 2. Abnormal glucose homeostasis in ECSHIP2Δ/+ mice. A) Fasting glucose was 
increased in ECSHIP2Δ/+ (n=7). B) Fasting insulin was comparable to control in ECSHIP2Δ/+ 
(n≥6). C) HOMA-IR was increased in ECSHIP2Δ/+ (n≥12). D) Glucose tolerance was 
impaired in ECSHIP2Δ/+ (n≥8). E) Insulin tolerance testing was similar in ECSHIP2Δ/+ versus 
control (n≥8). F) Serum free fatty acids were similar in ECSHIP2Δ/+ versus control (n≥6). G) 
Serum triglycerides were similar in ECSHIP2Δ/+ versus control (n≥6). 
 
Figure 3. Insulin resistance in ECSHIP2Δ/+ during hyperinsulinemic euglycemic 
clamping. A) Reduced insulin infusion rate (GIR) in ECSHIP2Δ/+ indicative of insulin 
resistance. B) Blunted glucose uptake in muscle and fat from ECSHIP2Δ/+. C,D) Comparable 
hepatic glucose output in ECSHIP2Δ/+ versus control (n≥4 for all experiments). 
 
Figure 4. Endothelial cell signaling insulin and mechanical shear stress signaling is 
impaired in ECSHIP2Δ/+. A) The basal abundance of Akt, pAkt T308, PDK1, pPDK1, 
 
Rictor, pRictor, eNOS and peNOS S1177 were increased in ECSHIP2Δ/+ EC exposed to 
standard culture media (n≥4). B) Insulin-stimulated [150nm for 10 minutes] phosphorylation 
of eNOS, but not Akt, was impaired in ECSHIP2Δ/+ EC (n≥6). C) Shear stress-induction [10 
minutes] of Akt and eNOS phosphorylation was impaired in ECSHIP2Δ/+ EC (n≥6). 
Representative Western blots are shown above all panels. 
 
Figure 5. Impaired aortic vasodilation in ECSHIP2Δ/+ is associated with oxidative stress 
and reduced NO bioavailability. A) Reduced insulin mediated aortic relaxation in 
ECSHIP2Δ/+ (n≥4). B-D) Reduced L-NMMA induced vasoconstriction in ECSHIP2Δ/+ 
indicative of reduced NO bioavailability (n≥3). E,F) Subtle impairment of acetylcholine-
mediated vasodilation in aorta from ECSHIP2Δ/+ (n≥8). F) No difference in SNP-mediated 
vasodilatation in aortic rings from ECSHIP2Δ/+ (n≥3). G-K) MnTmPYP blunts acetylcholine-
mediated vasodilation in aorta from ECSHIP2Δ/+ and controls, but the reduction in 
acetylcholine-mediated vasodilation is greater in ECSHIP2Δ/+ (n≥4). L) Increased aortic 
hydrogen peroxide generation in ECSHIP2Δ/+ (n≥4). 
 
Figure 6. ECSHIP2Δ/+ endothelial cells exhibit PI3K- and Nox2-dependent oxidative 
stress, and reduced nitric oxide generation. A) Increased superoxide generation in 
ECSHIP2Δ/+, measured with lucigenin-enhanced chemiluminescence (left: n≥10) and DHE 
fluorescence (right: n≥3). B) Increased Nox2 NADPH oxidase protein (Representative 
Western blot shown above panel) in ECSHIP2Δ/+ (n≥9). C) Increased superoxide abundance 
in ECSHIP2Δ/+ is normalized by Gp91ds-tat (n≥4). D) Increased superoxide abundance in 
ECSHIP2Δ/+ is normalized by the PI3K inhibitors Wortmannin and LY294002 (n≥4). E) 
Insulin-stimulated NO production is impaired in endothelial cells from ECSHIP2Δ/+ (n≥5). 
 
 
Figure 7. shRNA knockdown of SHIP2 in human umbilical vein endothelial cells 
(HUVEC) recapitulates phenotype of ECSHIP2Δ/+ endothelial cells. A) SHIP2 shRNA 
reduced SHIP2 protein by approximately 75%, versus control shRNA (n=3; Representative 
Western blot shown above panel). B) SHIP2 activity is reduced by SHIP2 shRNA (n=3). C) 
Increased superoxide abundance in SHIP2 knockdown HUVEC measured by lucigenin-
enhanced chemiluminescence (n=3). D) Increased Nox2 NADPH oxidase protein in SHIP2 
knockdown HUVEC (n=5; Representative Western blot shown above panel). E,F) 
Suppression of excess superoxide production in SHIP2 knockdown HUVEC by the NOX2 
inhibitor Gp91ds-tat, measured with lucigenin-enhanced chemiluminescence (E) (n≥3) and 
DHE fluorescence (F) (n=6). G) Increased concentration of S473 pAkt, S1177 peNOS in 
SHIP2 knockdown HUVEC (n=5). H) Suppression of excess superoxide production in SHIP2 
knockdown HUVEC by the PI3K inhibitors Wortmannin and LY294002 (n=5). 
 
Figure 8. Proposed mechanism of endothelial dysfunction associated with SHIP2 
knockdown. In contract with normal physiology (A), reduced SHIP2 activity (B) results in 
increased basal PI3K/Akt/eNOS signaling, although NOX2 is also hyper-activated, resulting 
in oxidative stress and reduced nitric oxide bioavailability. 
 
 
